Navigation Links
Multiple disease-related research gets green light from the NIH
Date:9/16/2008

Saranac Lake, N.Y. - Stephen Smiley, Ph.D., a member of the scientific faculty at the Trudeau Institute, whose research could lead to new treatments for several common diseases, has been awarded a research grant from the National Institutes of Health (NIH) for nearly $2 million.

Dr. Smiley and members of his laboratory are working to develop treatments for a number of diseases where an abnormal activation of blood coagulation pathways causes damage to the body. The diseases include multiple sclerosis (MS), rheumatoid arthritis, transplant rejection and sepsis, a leading cause of hospital deaths. In particular, Dr. Smiley's laboratory is studying fibrin, a blood-clotting protein that frequently accumulates at high levels in diseased tissues. These high levels of fibrin are thought to clog blood vessels and cause inflammation, thereby starving tissues of oxygen and increasing the severity of disease.

With prior funding from the NIH, Dr. Smiley's laboratory collaborated with Trudeau colleague Larry Johnson to demonstrate that, despite the risks it poses, fibrin also performs critical protective functions during immune responses.

The researchers showed that fibrin deposition is essential for survival during certain infections. Specifically, they found that fibrin staunches bleeding caused by protective immune cells as they rid the body of infected cells. In addition to protecting against this collateral damage caused by the immune system itself, Drs. Smiley and Johnson also discovered that fibrin suppresses the growth of some unhealthy bacteria.

These prior studies led the scientists to hypothesize that the human body needs to maintain a careful balance of proper fibrin levels during immune responses: "Some fibrin deposition is essential for good health, while too much can be dangerous and harmful," explained Dr. Smiley.

"I'm very pleased the NIH is continuing to support Dr. Smiley's research," said David L. Woodland, Ph.D., president and director of the Trudeau Institute. "Cutting-edge research of this caliber has the potential to lead to improved treatments for people afflicted with a number of debilitating diseases, in addition to those who suffer transplant rejections."

Dr. Smiley believes that prior attempts to treat patients suffering from sepsis by removing fibrin failed because those treatments most likely removed both unhealthy and healthy fibrin. With this infusion of research funds, Dr. Smiley's laboratory will now seek to identify what exactly tips the balance between healthy and unhealthy levels of fibrin. They recently discovered that cytokines, soluble signaling molecules within the immune system, play a primary role in regulating this balance. Now they are using a variety of models and methods to delineate precisely how cytokines regulate fibrin levels.

The NIH funds will support Dr. Smiley's research efforts over a four-year period.


'/>"/>

Contact: Brian Turner
brianturner@trudeauinstitute.org
518-891-3080
Trudeau Institute
Source:Eurekalert  

Related biology news :

1. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
2. Nicotinic receptors may be important targets for treatment of multiple addictions
3. Emphasis on conifer forests places multiple species at risk
4. For honey bee queens, multiple mating makes a difference
5. Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
6. New magnetic separation technique might detect multiple pathogens at once
7. The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source
8. Multiple species of bacteria may cause trachoma: Implications for treatment
9. Multiple resource management is focus of new technical report
10. Potential new target for multiple sclerosis therapy
11. Fast AFM probes measure multiple properties of biomolecules or materials simultaneously
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Multiple disease-related research gets green light from the NIH
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... Norwood, MA (PRWEB) , ... February 28, 2017 ... ... successful clinical trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial ... is celebrating 15 years of meeting this unique need within the biotechnology and ...
(Date:2/28/2017)... ... February 28, 2017 , ... GigaGen Inc ., a ... repertoires, today announced a strategic partnership with Trianni, Inc. , a biotechnology ... antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through ...
(Date:2/28/2017)... 28, 2017 Sangamo Therapeutics, Inc. (NASDAQ: ... reported its fourth quarter and full year 2016 ... this year we rebranded our company as Sangamo ... genomic therapies using our industry leading platform technologies ... cell therapy," said Sandy Macrae , CEO ...
(Date:2/27/2017)... VANCOUVER , Feb. 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, ... to their expiry on Friday, February 24, 2017 a total ... a price of $0.13 per common share. Proceeds from the ... were issued from InMed,s Treasury.   ... "We are grateful for this expression ...
Breaking Biology Technology: